Oxford Endovascular Crowned Winner Of "Perfect Pitch" At BioTrinity 2017 In London
11th May 2017, London, UK: OBN, the membership organisation that supports innovative life sciences companies, today announces that Mike Karim, CEO of Oxford Endovascular is the winner of Perfect Pitch, the fast-paced, interactive and lively pitching session which was a highlight of the BioTrinity 2017 conference programme.
Perfect Pitch involved ten emerging R&D companies pitch in front of a panel of seasoned investors including:
• Chair: Kate Bingham, Managing Partner, SV Life Sciences (UK)
• Maina Bhaman, Director of Healthcare Investment, Touchstone Innovations (UK)
• Kreske Nickelsen, General Partner & Chief Executive Officer, Joint Polish Investment Fund (Poland)
• Graeme Martin, Founder, HatchBox Bioconsulting LLC (US)
• Naveed Siddiqi, Partner, Edmond de Rothschild Investment Partners (UK/France)
• Andrew McLean, Principal Life Sciences Investor, Oxford Science Innovation (UK)
• Detlev Mennerich, Director and Investment Manager, Boehringer Ingelheim Ventures (Germany)
Each of the ten companies gave a strictly timed 3-minute presentation, with the judges selecting Mike Karim, CEO of Oxford Endovascular, Michael Stein, Chairman and CEO of Oxstem, Caroline Barelle, CEO of Elasmogen and Bert Rutten, COO of Lycotec to present in round two. After the final round of 2-minute presentations and further judges’ deliberations, Mike Karim of Oxford Endovascular was awarded the coveted Perfect Pitch winner’s trophy with Caroline Barelle awarded the runners-up position.
Mike Karim’s presentation described Oxford Endovascular’s development plan in metallic mesh tube devices, invented by engineers and clinicians at Oxford University to treat patients suffering from brain aneurysms. The judges commended him for his clear and convincing presentation style and the quality of his responses to questions asked.
Kate Bingham, Managing Partner, SV life Sciences, said: “The quality of this years’ Perfect Pitch session reflected the high calibre of company showcase presentations we saw at BioTrinity 2017. This fast-paced session is a fantastic platform for emerging entrepreneurs, with Mike Karim being selected based on the quality of his development programme as well as his confidence, style and engaging pitch.”
John Harris, Chief Executive Office of OBN, commented: “We applaud the talented individuals that competed in this year’s Perfect Pitch session, the quality was high and represent some of the most innovative emerging life sciences companies. Congratulations to Mike Karim, a very worthy winner indeed.”
The ten companies that presented their innovation included:
Michael Scherz, CEO, Metys Pharmaceuticals AG
Paul Colbon, CEO, Liverpool ChiroChem
Bert Rutten, COO, Lycotec
Mike Karim, CEO, Oxford Endovascular
Tim Mitchell, CEO, Sareum
Charles Potter, CEO, Unguis
Roy Farfara, CSO, Triox Nano
Michael Stein, Chairman and CEO, Oxstem
Will Dracup, CEO, Biosignatures
Caroline Barelle, CEO, Elasmogen
The End
Photos available upon request
Contacts
OBN
John Harris, CEO, OBN
Tel: +44 (0)7881 675990
Email: john.harris@obn.org.uk
Citigate Dewe Rogerson
Sylvie Berrebi
Tel: +44 (0)20 7638 9571
Email: Sylvie.Berrebi@citigatedr.co.uk
About OBN
OBN is the Membership organisation supporting and bringing together the UK’s innovative life sciences companies, corporate partners and investors. Our 400-plus member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland and benefit from our networking, partnering, purchasing, advising and advocacy activities. OBN is best known for its delivery of BioTrinity (the 12th edition is on 23-25 April 2018) Europe’s leading life sciences investment and biopartnering conference.
Further information about OBN’s tailored networking and partnering events, purchasing consortium, advice, consultancy services and advocacy activities is available on OBN’s website www.obn.org.uk
Perfect Pitch involved ten emerging R&D companies pitch in front of a panel of seasoned investors including:
• Chair: Kate Bingham, Managing Partner, SV Life Sciences (UK)
• Maina Bhaman, Director of Healthcare Investment, Touchstone Innovations (UK)
• Kreske Nickelsen, General Partner & Chief Executive Officer, Joint Polish Investment Fund (Poland)
• Graeme Martin, Founder, HatchBox Bioconsulting LLC (US)
• Naveed Siddiqi, Partner, Edmond de Rothschild Investment Partners (UK/France)
• Andrew McLean, Principal Life Sciences Investor, Oxford Science Innovation (UK)
• Detlev Mennerich, Director and Investment Manager, Boehringer Ingelheim Ventures (Germany)
Each of the ten companies gave a strictly timed 3-minute presentation, with the judges selecting Mike Karim, CEO of Oxford Endovascular, Michael Stein, Chairman and CEO of Oxstem, Caroline Barelle, CEO of Elasmogen and Bert Rutten, COO of Lycotec to present in round two. After the final round of 2-minute presentations and further judges’ deliberations, Mike Karim of Oxford Endovascular was awarded the coveted Perfect Pitch winner’s trophy with Caroline Barelle awarded the runners-up position.
Mike Karim’s presentation described Oxford Endovascular’s development plan in metallic mesh tube devices, invented by engineers and clinicians at Oxford University to treat patients suffering from brain aneurysms. The judges commended him for his clear and convincing presentation style and the quality of his responses to questions asked.
Kate Bingham, Managing Partner, SV life Sciences, said: “The quality of this years’ Perfect Pitch session reflected the high calibre of company showcase presentations we saw at BioTrinity 2017. This fast-paced session is a fantastic platform for emerging entrepreneurs, with Mike Karim being selected based on the quality of his development programme as well as his confidence, style and engaging pitch.”
John Harris, Chief Executive Office of OBN, commented: “We applaud the talented individuals that competed in this year’s Perfect Pitch session, the quality was high and represent some of the most innovative emerging life sciences companies. Congratulations to Mike Karim, a very worthy winner indeed.”
The ten companies that presented their innovation included:
Michael Scherz, CEO, Metys Pharmaceuticals AG
Paul Colbon, CEO, Liverpool ChiroChem
Bert Rutten, COO, Lycotec
Mike Karim, CEO, Oxford Endovascular
Tim Mitchell, CEO, Sareum
Charles Potter, CEO, Unguis
Roy Farfara, CSO, Triox Nano
Michael Stein, Chairman and CEO, Oxstem
Will Dracup, CEO, Biosignatures
Caroline Barelle, CEO, Elasmogen
The End
Photos available upon request
Contacts
OBN
John Harris, CEO, OBN
Tel: +44 (0)7881 675990
Email: john.harris@obn.org.uk
Citigate Dewe Rogerson
Sylvie Berrebi
Tel: +44 (0)20 7638 9571
Email: Sylvie.Berrebi@citigatedr.co.uk
About OBN
OBN is the Membership organisation supporting and bringing together the UK’s innovative life sciences companies, corporate partners and investors. Our 400-plus member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland and benefit from our networking, partnering, purchasing, advising and advocacy activities. OBN is best known for its delivery of BioTrinity (the 12th edition is on 23-25 April 2018) Europe’s leading life sciences investment and biopartnering conference.
Further information about OBN’s tailored networking and partnering events, purchasing consortium, advice, consultancy services and advocacy activities is available on OBN’s website www.obn.org.uk